CA2667039A1 - Composition de comprimes a multiples unites de composes de benzimidazole - Google Patents

Composition de comprimes a multiples unites de composes de benzimidazole Download PDF

Info

Publication number: CA2667039A1
Authority: CA; Canada
Prior art keywords: enteric coating; coating layer; composition according; core; plasticizer
Prior art date: 2006-10-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002667039A

Other languages

English (en)

Inventor

Sachin Gahoi

Raveendra Pai M

Khalid Rafi

Ajay Kumar Singla

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ranbaxy Laboratories Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-17

Filing date

2007-10-17

Publication date

2008-04-24

2007-10-17 Application filed by Individual filed Critical Individual

2008-04-24 Publication of CA2667039A1 publication Critical patent/CA2667039A1/fr

Status Abandoned legal-status Critical Current

Links

239000007916 tablet composition Substances 0.000 title claims abstract description 15
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 title abstract description 5
239000010410 layer Substances 0.000 claims abstract description 98
239000002702 enteric coating Substances 0.000 claims abstract description 84
238000009505 enteric coating Methods 0.000 claims abstract description 84
239000000203 mixture Substances 0.000 claims abstract description 54
239000004014 plasticizer Substances 0.000 claims abstract description 33
229920000642 polymer Polymers 0.000 claims abstract description 29
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 26
-1 benzimidazole compound Chemical class 0.000 claims abstract description 23
238000000034 method Methods 0.000 claims abstract description 19
230000008569 process Effects 0.000 claims abstract description 15
238000002360 preparation method Methods 0.000 claims abstract description 12
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 28
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 28
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 28
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 26
235000000346 sugar Nutrition 0.000 claims description 21
229960000913 crospovidone Drugs 0.000 claims description 20
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 20
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 20
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 17
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
239000000454 talc Substances 0.000 claims description 17
229910052623 talc Inorganic materials 0.000 claims description 17
229940033134 talc Drugs 0.000 claims description 17
235000012222 talc Nutrition 0.000 claims description 17
229920001223 polyethylene glycol Polymers 0.000 claims description 15
239000011248 coating agent Substances 0.000 claims description 14
238000000576 coating method Methods 0.000 claims description 14
239000011247 coating layer Substances 0.000 claims description 13
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 12
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 11
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
229940045902 sodium stearyl fumarate Drugs 0.000 claims description 11
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 10
229920002261 Corn starch Polymers 0.000 claims description 9
239000001913 cellulose Substances 0.000 claims description 9
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
239000011230 binding agent Substances 0.000 claims description 8
239000000314 lubricant Substances 0.000 claims description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
239000008108 microcrystalline cellulose Substances 0.000 claims description 8
229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
229930195725 Mannitol Natural products 0.000 claims description 7
229920001577 copolymer Polymers 0.000 claims description 7
239000007884 disintegrant Substances 0.000 claims description 7
239000000594 mannitol Substances 0.000 claims description 7
235000010355 mannitol Nutrition 0.000 claims description 7
239000000600 sorbitol Substances 0.000 claims description 7
235000010356 sorbitol Nutrition 0.000 claims description 7
235000010980 cellulose Nutrition 0.000 claims description 6
229920002678 cellulose Polymers 0.000 claims description 6
239000008120 corn starch Substances 0.000 claims description 6
150000008163 sugars Chemical class 0.000 claims description 6
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
229940099112 cornstarch Drugs 0.000 claims description 5
239000000945 filler Substances 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 5
229960000381 omeprazole Drugs 0.000 claims description 5
YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 4
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
239000008121 dextrose Substances 0.000 claims description 4
239000008103 glucose Substances 0.000 claims description 4
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
235000019359 magnesium stearate Nutrition 0.000 claims description 4
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
239000000811 xylitol Substances 0.000 claims description 4
235000010447 xylitol Nutrition 0.000 claims description 4
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
229960002675 xylitol Drugs 0.000 claims description 4
244000215068 Acacia senegal Species 0.000 claims description 3
235000006491 Acacia senegal Nutrition 0.000 claims description 3
241000416162 Astragalus gummifer Species 0.000 claims description 3
229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
229920000084 Gum arabic Polymers 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
235000019759 Maize starch Nutrition 0.000 claims description 3
229920000881 Modified starch Polymers 0.000 claims description 3
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 3
229920001615 Tragacanth Polymers 0.000 claims description 3
235000010489 acacia gum Nutrition 0.000 claims description 3
229960001681 croscarmellose sodium Drugs 0.000 claims description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
229960003174 lansoprazole Drugs 0.000 claims description 3
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 3
229940057948 magnesium stearate Drugs 0.000 claims description 3
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
229960005019 pantoprazole Drugs 0.000 claims description 3
229920003124 powdered cellulose Polymers 0.000 claims description 3
235000019814 powdered cellulose Nutrition 0.000 claims description 3
229960004157 rabeprazole Drugs 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
239000008109 sodium starch glycolate Substances 0.000 claims description 3
229920003109 sodium starch glycolate Polymers 0.000 claims description 3
229940079832 sodium starch glycolate Drugs 0.000 claims description 3
150000005846 sugar alcohols Chemical class 0.000 claims description 3
235000010487 tragacanth Nutrition 0.000 claims description 3
239000000196 tragacanth Substances 0.000 claims description 3
229940116362 tragacanth Drugs 0.000 claims description 3
235000010493 xanthan gum Nutrition 0.000 claims description 3
239000000230 xanthan gum Substances 0.000 claims description 3
229920001285 xanthan gum Polymers 0.000 claims description 3
229940082509 xanthan gum Drugs 0.000 claims description 3
PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 2
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
229960000541 cetyl alcohol Drugs 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2
229940031954 dibutyl sebacate Drugs 0.000 claims description 2
230000027119 gastric acid secretion Effects 0.000 claims description 2
239000001087 glyceryl triacetate Substances 0.000 claims description 2
235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
159000000011 group IA salts Chemical class 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
229950007395 leminoprazole Drugs 0.000 claims description 2
229940068917 polyethylene glycols Drugs 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
229940068965 polysorbates Drugs 0.000 claims description 2
229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
239000012453 solvate Substances 0.000 claims description 2
229960002622 triacetin Drugs 0.000 claims description 2
HLKZFSVWBQSKKH-UHFFFAOYSA-N but-3-enoic acid;1-ethenylpyrrolidin-2-one Chemical compound OC(=O)CC=C.C=CN1CCCC1=O HLKZFSVWBQSKKH-UHFFFAOYSA-N 0.000 claims 1
150000003022 phthalic acids Chemical class 0.000 claims 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 64
239000011324 bead Substances 0.000 description 49
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
239000006185 dispersion Substances 0.000 description 36
239000003826 tablet Substances 0.000 description 35
239000011162 core material Substances 0.000 description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
239000008213 purified water Substances 0.000 description 23
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
239000000463 material Substances 0.000 description 14
239000002202 Polyethylene glycol Substances 0.000 description 13
238000007906 compression Methods 0.000 description 13
230000006835 compression Effects 0.000 description 13
239000003814 drug Substances 0.000 description 13
229940079593 drug Drugs 0.000 description 12
239000007888 film coating Substances 0.000 description 10
238000009501 film coating Methods 0.000 description 10
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 8
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
239000003085 diluting agent Substances 0.000 description 8
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
238000003756 stirring Methods 0.000 description 8
239000002253 acid Substances 0.000 description 7
229960000197 esomeprazole magnesium Drugs 0.000 description 7
238000009472 formulation Methods 0.000 description 7
KWORUUGOSLYAGD-WLHYKHABSA-N magnesium;5-methoxy-2-[(r)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-WLHYKHABSA-N 0.000 description 7
239000002245 particle Substances 0.000 description 7
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 6
229960004770 esomeprazole Drugs 0.000 description 6
SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 6
239000012535 impurity Substances 0.000 description 6
238000003860 storage Methods 0.000 description 6
150000001556 benzimidazoles Chemical class 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229920003134 Eudragit® polymer Polymers 0.000 description 4
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
239000008118 PEG 6000 Substances 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000010907 mechanical stirring Methods 0.000 description 4
239000008188 pellet Substances 0.000 description 4
229920000573 polyethylene Polymers 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
239000001069 triethyl citrate Substances 0.000 description 4
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
235000013769 triethyl citrate Nutrition 0.000 description 4
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
SXLXFQHJSPDNPD-UHFFFAOYSA-N calcium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Ca].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SXLXFQHJSPDNPD-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000007931 coated granule Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
229920003136 Eudragit® L polymer Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
229940121819 ATPase inhibitor Drugs 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
108010083204 Proton Pumps Proteins 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
229910000323 aluminium silicate Inorganic materials 0.000 description 1
UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 description 1
RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
239000002216 antistatic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000005336 cracking Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
229960001545 hydrotalcite Drugs 0.000 description 1
229910001701 hydrotalcite Inorganic materials 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
150000003021 phthalic acid derivatives Chemical class 0.000 description 1
239000000049 pigment Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA002667039A 2006-10-17 2007-10-17 Composition de comprimes a multiples unites de composes de benzimidazole Abandoned CA2667039A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN2279DE2006		2006-10-17
IN2279/DEL/2006		2006-10-17
PCT/IB2007/054233 WO2008047320A2 (fr)	2006-10-17	2007-10-17	Composition de comprimés à multiples unités de composés de benzimidazole

Publications (1)

Publication Number	Publication Date
CA2667039A1 true CA2667039A1 (fr)	2008-04-24

Family

ID=39271195

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002667039A Abandoned CA2667039A1 (fr)	2006-10-17	2007-10-17	Composition de comprimes a multiples unites de composes de benzimidazole

Country Status (5)

Country	Link
EP (1)	EP2081546A2 (fr)
AU (1)	AU2007311493B2 (fr)
BR (1)	BRPI0717613A2 (fr)
CA (1)	CA2667039A1 (fr)
WO (1)	WO2008047320A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130122090A1 (en)	2010-07-22	2013-05-16	Lupin Limited	Multiple Unit Tablet Composition
US20170042806A1 (en)	2015-04-29	2017-02-16	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
DK0723436T3 (da) *	1994-07-08	2001-11-26	Astrazeneca Ab	Tabletteret flerenhedsdoseringsform
WO1996007421A2 (fr) *	1994-09-09	1996-03-14	Takeda Chemical Industries, Ltd.	Medicament anti-ulcereux comprenant une proteine ayant une activite de facteur de croissance cellulaire et un inhibiteur de la pompe a protons
FR2774288B1 (fr) *	1998-01-30	2001-09-07	Ethypharm Sa	Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6228400B1 (en) *	1999-09-28	2001-05-08	Carlsbad Technology, Inc.	Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
PE20050150A1 (es) *	2003-05-08	2005-03-22	Altana Pharma Ag	Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo

2007
- 2007-10-17 EP EP07826778A patent/EP2081546A2/fr not_active Withdrawn
- 2007-10-17 BR BRPI0717613-9A2A patent/BRPI0717613A2/pt not_active IP Right Cessation
- 2007-10-17 AU AU2007311493A patent/AU2007311493B2/en not_active Withdrawn - After Issue
- 2007-10-17 CA CA002667039A patent/CA2667039A1/fr not_active Abandoned
- 2007-10-17 WO PCT/IB2007/054233 patent/WO2008047320A2/fr not_active Ceased

Also Published As

Publication number	Publication date
EP2081546A2 (fr)	2009-07-29
WO2008047320A3 (fr)	2008-06-19
BRPI0717613A2 (pt)	2013-10-22
WO2008047320A2 (fr)	2008-04-24
AU2007311493B2 (en)	2013-01-31
AU2007311493A1 (en)	2008-04-24

Legal Events

Date	Code	Title	Description
2012-10-10	EEER	Examination request
2016-07-06	FZDE	Dead	Effective date: 20160525

Publication	Publication Date	Title
US6610323B1 (en)	2003-08-26	Oral pharmaceutical pulsed release dosage form
CA2213987C (fr)	2006-08-15	Formes galeniques pharmaceutiques orales comprenant un inhibiteur de pompe a protons et un anti-inflammatoire non steroidien
JP3350054B2 (ja)	2002-11-25	複数単位の錠剤化された剤形▲ｉ▼
JPH09502740A (ja)	1997-03-18	プロトンポンプ抑制剤を含有する複数単位の製剤
US20100178334A1 (en)	2010-07-15	Oral Pharmaceutical Dosage Form Comprising as Active Ingredients a Proton Pump Inhibitor together with Acetyl Salicyclic Acid
WO2014016754A2 (fr)	2014-01-30	Compositions pharmaceutiques d'inhibiteur de la pompe à protons
WO2011140446A2 (fr)	2011-11-10	Formulations pharmaceutiques
WO2004071374A2 (fr)	2004-08-26	Compositions pharmaceutiques d'administration orale une fois par jour
WO2011144975A1 (fr)	2011-11-24	Compositions multi-unités
US20110177164A1 (en)	2011-07-21	Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
WO2010041276A1 (fr)	2010-04-15	Compositions pharmaceutiques comprenant de l’ésoméprazole amorphe, formes pharmaceutiques et procédé associés
US20120164233A1 (en)	2012-06-28	Pulsatile release pharmaceutical formulation of dexlansoprazole
AU2007311493B2 (en)	2013-01-31	Multiple unit tablet compositions of benzimidazole compounds
EP1594479A1 (fr)	2005-11-16	Compositions orales stables de benzimidazole et leurs procedes de preparation
US8658216B2 (en)	2014-02-25	Stable oral benzimidazole compositions and process of preparation thereof
WO2011138797A2 (fr)	2011-11-10	Composition pharmaceutique de lansoprazole à action différée se désintégrant par la voie buccale
US8911787B2 (en)	2014-12-16	Stable oral benzimidazole compositions and process of preparation thereof
US20120321702A1 (en)	2012-12-20	Pharmaceutical composition of lansoprazole
CA2547398A1 (fr)	2005-06-09	Compositions stables de benzimidazole a administration orale et leurs procedes de preparation
WO2004089333A2 (fr)	2004-10-21	Formulation de benzimidazole stable
WO2010018593A2 (fr)	2010-02-18	Composition de comprimé de benzimidazole à unités multiples résistante à l'acide gastrique
US20080279951A1 (en)	2008-11-13	Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
CA2623560A1 (fr)	2008-08-28	Procede de preparation d'une composition stable et amorphe de benzimidazole